SIA
SVA

Stancorp Investment Advisers’s Sinovac Biotech, Ltd SVA Stock Holding History

Stancorp Investment Advisers’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$8K Hold
1,637
– – ﹤0.01% 489
2014
Q4 		$9K Buy
+1,637
New +$8.35K ﹤0.01% 449

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Zurich Cantonal Bank
Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return

Stancorp Investment Advisers's SVA Position: Q1 2015 in Review

Stancorp Investment Advisers held its Sinovac Biotech, Ltd (SVA) position steady in Q1 2015 at 1,637 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #489.

Stancorp Investment Advisers first reported a position in SVA in Q4 2014 and has held it in 2 quarters since. The position peaked at $9K in Q4 2014. 40 funds tracked by Wall St. Rank hold SVA as of Q1 2015.

  • Stancorp Investment Advisers held 1,637 shares of Sinovac Biotech, Ltd worth $8K as of Q1 2015.
  • Stancorp Investment Advisers left its Sinovac Biotech, Ltd share count unchanged in Q1 2015.
  • Sinovac Biotech, Ltd made up ﹤0.01% of Stancorp Investment Advisers's portfolio in Q1 2015, its #489 holding.
  • Stancorp Investment Advisers first reported a position in Sinovac Biotech, Ltd in Q4 2014 and has held it in 2 quarters since.
  • Stancorp Investment Advisers's Sinovac Biotech, Ltd position peaked at $9K in Q4 2014.
  • 40 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2015.

Based on Stancorp Investment Advisers's 13F filing for Q1 2015, filed 13 May 2015.